Wegovy vs Compounded Semaglutide: 2026 Cost Comparison
Wegovy and compounded semaglutide share the same active ingredient at very different prices. Here’s the 2026 cost comparison, the real differences, and how to choose.
The cost comparison
| Option | Monthly cost (cash) |
|---|---|
| Wegovy retail | ~$1,349 |
| Ozempic retail | ~$969 |
| NovoCare / oral semaglutide | ~$149–$499 |
| Compounded semaglutide (median) | ~$179 |
| Compounded semaglutide (lowest flat credentialed) | $145 (NexLife) |
| Compounded semaglutide (lowest sticker) | $99 (Embody) |
For a cash-pay patient, compounded semaglutide is typically the lowest-cost route — 80–90% below Wegovy retail. Novo’s 2026 cash-pay programs narrowed the gap, so weigh both.
What’s the same
Both are semaglutide, the GLP-1 receptor agonist studied in STEP-1 and SELECT. The molecule and its efficacy — including the ~20% cardiovascular risk reduction in SELECT — are identical. See the science.
What’s different
- FDA approval: Wegovy is FDA-approved; compounded semaglutide is not.
- Form: Wegovy is a fixed-dose pen; compounded is typically a dose-flexible vial.
- Quality assurance: Wegovy is cGMP-manufactured; compounded quality depends on the pharmacy.
- Legal status: broad compounding is restricted in 2026 (details).
Which is cheaper for you
- Have insurance coverage for Wegovy: brand after copay may be cheapest.
- Cash-pay: compounded semaglutide is usually the lowest-cost legal route.
- Want FDA-approved without insurance: NovoCare cash-pay options bridge the gap.
See the full compounded vs brand analysis and the semaglutide price guide.
Bottom line
Wegovy and compounded semaglutide are the same molecule at very different prices. Insured patients may pay least for Wegovy; cash-pay patients usually pay least for compounded — from a verified, compliant provider.
Educational, not medical advice. Wegovy and Ozempic are registered trademarks of Novo Nordisk. Compounded medications are not FDA-approved.
Independent & transparent
This website is independently operated and is not owned by, affiliated with, or paid by any provider listed. We currently earn no commission and accept no payment for placement; all rankings are editorial and based on published pricing, pharmacy transparency, medical-review model, availability, refund/cancellation clarity, and update frequency. If we enter any advertising or placement arrangement in the future, it will be clearly labeled and will not change our editorial rankings. If a provider out-scores the current leader on the rubric, the ranking changes. See our methodology → · Who pays us →